Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants - PubMed (original) (raw)
Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants
Huei-Fung Tsai et al. Antimicrob Agents Chemother. 2006 Apr.
Abstract
Candida glabrata, a yeast with intrinsically low susceptibility to azoles, frequently develops increased azole resistance during prolonged treatment. Transposon mutagenesis revealed that disruption of CgPDR1 resulted in an 8- to 16-fold increase in fluconazole susceptibility of C. glabrata. CgPDR1 is a homolog of Saccharomyces cerevisiae PDR1, which encodes a transcriptional regulator of multidrug transporters. Northern blot analyses indicated that CgPDR1 regulated both constitutive and drug-induced expression of CgCDR1, a multidrug transporter gene. In agreement with the Northern analysis, the Cgpdr1 mutant had increased rhodamine accumulation, in contrast to the decreased accumulation in the CgPDR1-overexpressing strain. Northern analyses also indicated the importance of CgPDR1 in fluconazole resistance arising during therapy. Two clinically resistant isolates had higher expression of CgPDR1 and CgCDR1 compared to their paired susceptible isolates. Integrative transformation of CgPDR1 from the two resistant isolates converted the Cgpdr1 mutant into azole-resistant strains with upregulated CgPDR1 expression. Two different amino acid substitutions, W297S in one isolate and F575L in the other, accounted for the upregulated CgPDR1 expression and the resistance. Finally, CgPDR1 was shown to be required for the azole resistance due to mitochondrial deficiency. Thus, CgPDR1 encodes a transcriptional regulator of a pleiotropic drug resistance network and contributes to the azole resistance of clinical isolates and petite mutants.
Figures
FIG. 1.
Southern hybridization analysis confirmed the disruption and targeted replacement of PDR1 in C. glabrata. (A) Restriction enzyme map. (B) Southern blot analysis. Total DNA was digested with BglII. The membrane was hybridized with the 2.9-kb Tn_5_ (left panel) or 1.3-kb BglII Cg_PDR1_ (right panel) probe. Lanes: 1, strain NCCLS84, C. glabrata laboratory wild-type strain; 2, strain CgB4, Cg_pdr1_ mutant; 3, strain Cg173C, CgB4 complemented with Cg_PDR1_ of clinical fluconazole-resistant isolate Cg13928. An asterisk indicates the codon mutations in the clinical fluconazole-resistant isolates, W297S in Cg4672 and F575L in Cg13928.
FIG. 2.
Overexpression of Cg_PDR1_ in the pdr1 mutant of S. cerevisiae reduced its sensitivities to fluconazole and rhodamine 6G. A disk diffusion assay was used to determine the drug sensitivities of S. cerevisiae strains. Strains: BY4741, wild type; 4381, pdr1 mutant; 4381/pH392, pdr1 mutant carrying the vector pH392; 4381/pHCgPDR1, pdr1 mutant carrying the Cg_PDR1_ overexpression cassette ADH1p _-Cg_PDR1-ADH1T. FLC, fluconazole; R6G, rhodamine 6G. Plates were photographed after 2 days of incubation at 30°C. WT, wild type.
FIG. 3.
Disruption or overexpression of Cg_PDR1_ altered the expression of Cg_CDR1_ and PDH1. Northern hybridization analyses were used to determine the expression of Cg_PDR1_, Cg_CDR1_, and PDH1. Ten micrograms of total RNA was used for Northern blot analysis. The membrane was hybridized with the following probe: 2.3-kb BglII Cg_PDR1_ DNA (top panel), 1.1-kb NotI-BamHI Cg_CDR1_ DNA from pCRScript-CDR1 (14) (middle panel), or 3.6-kb PDH1 DNA from pClaI (25) (bottom panel). Sizes of putative transcripts are indicated in kilobases on the right. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3, strain CgB4/pCgACU, Cg_pdr1_ mutant carrying the vector pCgACU; 4, strain CgB4/pCgPDR1, Cg_pdr1_ mutant overexpressing Cg_PDR1_. WT, wild type.
FIG. 4.
Cycloheximide- and oligomycin-induced Cg_CDR1_ expression depended on Cg_PDR1_. Ten micrograms of total RNA was used for the Northern hybridization analysis to determine the level of drug-induced Cg_CDR1_ expression. The membrane was hybridized with the 1.1-kb NotI-BamHI Cg_CDR1_ DNA probe. The sizes of putative transcripts are indicated in kilobases. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1 to 4, NCCLS84 (wild type); 5 to 8, CgB4 (Cg_pdr1_ mutant). CHX, cycloheximide; OLI, oligomycin; R6G, rhodamine 6G. WT, wild type.
FIG. 5.
Altered drug sensitivity in C. glabrata caused by the disruption or overexpression of Cg_PDR1_. Disk diffusion assay was used to determine the drug sensitivity of C. glabrata. Strains: NCCLS84, wild type; 84870, Cg_cdr1_ and pdh1 double disruptant; CgB4, Cg_pdr1_ mutant; CgB4u/pCgACU, Cg_pdr1_ carrying the vector pCgACU; CgB4u/pCgPDR1, Cg_pdr1_ mutant overexpressing Cg_PDR1_. FLC, fluconazole; R6G, rhodamine 6G; CHX, cycloheximide; CHL, chloramphenicol; CRN, cerulenin. Plates were photographed after 2 days of incubation at 30°C. WT, wild type.
FIG. 6.
Clinical fluconazole-resistant isolates overexpressed Cg_PDR1_ and Cg_CDR1_. Two pairs of clinical isolates, Cg1660 versus Cg4672 and Cg12581 versus Cg13928, were analyzed by Northern blot hybridization along with NCCLS84. Probes used for each Northern blot are labeled on the left, and the estimated sizes of hybridized transcripts in kilobases are labeled on the right. The rRNA stained with ethidium bromide was used as the loading control. Probes: top, 2.3-kb Bgl_II Cg_PDR1 DNA; bottom, 1.1-kb NotI-BamHI Cg_CDR1_ DNA.
FIG. 7.
W297S or F595L single-amino-acid substitution of CgPdr1p led to upregulated expression of Cg_PDR1_ and Cg_CDR1_. The expression of Cg_PDR1_ and Cg_CDR1_ was analyzed by Northern blot analysis. The membrane was hybridized with the 2.9-kb HindIII Cg_PDR1_ DNA or 1.1-kb NotI-BamHI Cg_CDR1_ DNA probe. The rRNA stained with ethidium bromide was used as the loading control. All complementations were done with integrative transformation. (A) Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3 and 4, strain CgB4Ca12581 and strain CgB4Cb12581, CgB4 complemented by Cg_PDR1_ from Cg12581; 5 and 6, strain CgB4Ca13928 and strain CgB4Cb13928, CgB4 complemented by Cg_PDR1_ from Cg13928. (B) Lanes: 1, strain NCCLS84, wild type; 2, strain CgB4, Cg_pdr1_ mutant; 3 and 4, strain CgB4Ca1660 and strain CgB4Cb1660, CgB4 complemented by Cg_PDR1_ from Cg1660; 5 and 6, strain CgB4Ca4672 and strain CgB4Cb4672, CgB4 complemented by Cg_PDR1_ from Cg4672. WT, wild type.
FIG. 8.
Cg_PDR1_ is required for upregulated expression of PDR genes caused by mitochondrial dysfunction. For Northern blot analysis, the membrane was hybridized with the 2.3-kb BglII Cg_PDR1_ DNA (top) or 2.3-kb BamHI-NotI Cg_CDR1_ (bottom) probe. The rRNA stained with ethidium bromide was used as the loading control. Lanes: 1, strain NCCLS84, wild type; 2 and 3, petite mutant strains derived from NCCLS84; 5, strain CgB4, Cg_pdr1_ mutant; 6 to 8, petite mutant strains derived from CgB4.
Similar articles
- Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.
Tsai HF, Sammons LR, Zhang X, Suffis SD, Su Q, Myers TG, Marr KA, Bennett JE. Tsai HF, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3308-17. doi: 10.1128/AAC.00535-10. Epub 2010 Jun 14. Antimicrob Agents Chemother. 2010. PMID: 20547810 Free PMC article. - Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients.
Tantivitayakul P, Lapirattanakul J, Kaypetch R, Muadcheingka T. Tantivitayakul P, et al. J Glob Antimicrob Resist. 2019 Jun;17:221-226. doi: 10.1016/j.jgar.2019.01.006. Epub 2019 Jan 15. J Glob Antimicrob Resist. 2019. PMID: 30658200 - Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.
Vermitsky JP, Edlind TD. Vermitsky JP, et al. Antimicrob Agents Chemother. 2004 Oct;48(10):3773-81. doi: 10.1128/AAC.48.10.3773-3781.2004. Antimicrob Agents Chemother. 2004. PMID: 15388433 Free PMC article. - Multiple interfaces control activity of the Candida glabrata Pdr1 transcription factor mediating azole drug resistance.
Moye-Rowley WS. Moye-Rowley WS. Curr Genet. 2019 Feb;65(1):103-108. doi: 10.1007/s00294-018-0870-4. Epub 2018 Jul 28. Curr Genet. 2019. PMID: 30056490 Free PMC article. Review.
Cited by
- Similarities and distinctions in the activation of the Candida glabrata Pdr1 regulatory pathway by azole and non-azole drugs.
Conway TP, Vu BG, Beattie SR, Krysan DJ, Moye-Rowley WS. Conway TP, et al. bioRxiv [Preprint]. 2024 Sep 19:2024.09.19.613905. doi: 10.1101/2024.09.19.613905. bioRxiv. 2024. PMID: 39345512 Free PMC article. Preprint. - Drug tolerance and persistence in bacteria, fungi and cancer cells: Role of non-genetic heterogeneity.
El Meouche I, Jain P, Jolly MK, Capp JP. El Meouche I, et al. Transl Oncol. 2024 Nov;49:102069. doi: 10.1016/j.tranon.2024.102069. Epub 2024 Aug 8. Transl Oncol. 2024. PMID: 39121829 Free PMC article. - Molecular mechanisms governing antifungal drug resistance.
Lee Y, Robbins N, Cowen LE. Lee Y, et al. NPJ Antimicrob Resist. 2023;1(1):5. doi: 10.1038/s44259-023-00007-2. Epub 2023 Jul 17. NPJ Antimicrob Resist. 2023. PMID: 38686214 Free PMC article. Review. - Functional genetic characterization of stress tolerance and biofilm formation in Nakaseomyces (Candida) glabrata via a novel CRISPR activation system.
Maroc L, Shaker H, Shapiro RS. Maroc L, et al. mSphere. 2024 Feb 28;9(2):e0076123. doi: 10.1128/msphere.00761-23. Epub 2024 Jan 24. mSphere. 2024. PMID: 38265239 Free PMC article. - Modulators of Candida albicans Membrane Drug Transporters: A Lucrative Portfolio for the Development of Effective Antifungals.
Jaiswal N, Kumar A. Jaiswal N, et al. Mol Biotechnol. 2024 May;66(5):960-974. doi: 10.1007/s12033-023-01017-1. Epub 2024 Jan 11. Mol Biotechnol. 2024. PMID: 38206530 Review.
References
- Balzi, E., W. Chen, S. Ulaszewski, E. Capieaux, and A. Goffeau. 1987. The multidrug resistance gene PDR1 from Saccharomyces cerevisiae. J. Biol. Chem. 262:16871-16879. - PubMed
- Brachmann, C. B., A. Davies, G. J. Cost, E. Caputo, J. Li, P. Hieter, and J. D. Boeke. 1998. Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 14:115-132. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases